{
    "Trade/Device Name(s)": [
        "Elecsys CA 15-3 II",
        "Elecsys Cancer Antigen 15-3 II"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K181492",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171605"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MOI"
    ],
    "Summary Letter Date": "June 5, 2018",
    "Summary Letter Received Date": "June 6, 2018",
    "Submission Date": "May 10, 2018",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 15-3"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Li-heparin plasma",
        "EDTA plasma",
        "K2-EDTA plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "cobas e 801 immunoassay analyzer",
        "cobas e immunoassay analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Electrochemiluminescence detection",
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "System",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys CA 15-3 II electrochemiluminescence immunoassay for quantitative measurement of CA 15-3 in serum and plasma to aid management of breast cancer patients",
    "Indications for Use Summary": "Quantitative in vitro determination of CA 15-3 in human serum, Li-heparin and EDTA plasma to aid in the management of breast cancer patients, including early detection of recurrence in previously treated stage II and III cases and for monitoring therapy response in metastatic cases, for use on cobas e immunoassay analyzers",
    "fda_folder": "Immunology"
}